Thalidomide is a poor substrate for cytochrome P450 isoenzymes and therefore clinically important interactions with medicinal products metabolized by this enzyme system are unlikely.
Talidomid je slab substrat za izoencime citokroma P450, zato je verjetnost klinično pomembnih interakcij z zdravili, ki jih metabolizira ta encimski sistem, majhna.